ArticleRSC medicinal chemistry2023
Target 2035 - an update on private sector contributions.
Abstract readEditorial
In one paragraph
Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Atomic-level protein-ligand recognition with PBCNet2.0 for probe discovery.Nature chemical biology · 2026Article
- Unveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning.Acta pharmaceutica Sinica. B · 2026Article
- Scaling covalent ligand discovery through dynamic combinatorial library-versus-proteome screening.Nature communications · 2026Article
- Accurate Identification of Protein Binding Sites for All Drug Modalities Using ALLSites.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in sulfonyl exchange chemical biology: expanding druggable target space.Chemical science · 2025Review
- Chemical Switching: A Concept Inspired by Strategies from Biocatalysis and Organocatalysis.Chembiochem : a European journal of chemical biology · 2025Review
- Toward target 2035: EUbOPEN - a public-private partnership to enable & unlock biology in the open.RSC medicinal chemistry · 2025Article
- A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.Journal of medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors.
Suzanne AcklooStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.ORCID https://orcid.org/0000-0002-9696-1839
Albert A AntolinProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL) L'Hospitalet del Llobregat Barcelona Catalonia Spain aantolin@idibell.cat.ORCID https://orcid.org/0000-0002-1634-9034
Jose Manuel BartolomeA Division of Janssen-Cilag S.A., Janssen Research and Development Toledo Spain jbartolo@its.jnj.com JLlaveri@ITS.JNJ.com.ORCID https://orcid.org/0000-0002-5536-9951
Hartmut BeckResearch and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com.ORCID https://orcid.org/0000-0002-7826-8467
Alex BullockCenter for Medicines Discovery, Old Road Campus, University of Oxford Roosevelt Drive, Headington Oxford OX3 7DQ UK alex.bullock@cmd.ox.ac.uk jon.elkins@cmd.ox.ac.uk.ORCID https://orcid.org/0000-0001-6757-0436
Ulrich A K BetzMerck KGaA Darmstadt Germany ulrich.betz@merckgroup.com Sven.Lindemann@merckgroup.com.
Jark BöttcherBoehringer Ingelheim RCV GmbH & Co KG Vienna Austria jark.boettcher@boehringer-ingelheim.com.ORCID https://orcid.org/0000-0003-2189-5926
Peter J BrownStructural Genomics Consortium, University of North Carolina at Chapel Hill USA peter.brown@unc.edu.ORCID https://orcid.org/0000-0002-8454-0367
Menorca ChaturvediBoehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com.ORCID https://orcid.org/0000-0002-2865-2161
Alisa CrispDivision of Cancer Therapeutics, The Institute of Cancer Research London SM2 5NG UK Alisa.crisp@icr.ac.uk.
Danette DanielsFoghorn Therapeutics 500 Technology Square, Suite 700 Cambridge MA 02139 USA DDaniels@foghorntx.com.ORCID https://orcid.org/0000-0002-7659-3020
Jan DreherResearch and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com.ORCID https://orcid.org/0000-0001-8588-2564
Kristina EdfeldtStructural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden kristina.edfeldt@ki.se michael.sundstrom@ki.se.ORCID https://orcid.org/0000-0002-0550-1133
Aled M EdwardsStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.ORCID https://orcid.org/0000-0002-4782-6016
Ursula EgnerNuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany egner.target2035@web.de anke.mueller-fahrnow@nuvisan.com.
Jon ElkinsCenter for Medicines Discovery, Old Road Campus, University of Oxford Roosevelt Drive, Headington Oxford OX3 7DQ UK alex.bullock@cmd.ox.ac.uk jon.elkins@cmd.ox.ac.uk.
Christian FischerDiscovery Chemistry, Merck & Co., Inc. Boston Massachusetts 02115 USA christian_fischer@merck.com.
Tine GlendorfResearch & Early Development, Novo Nordisk A/S Måløv Denmark tgle@novonordisk.com lrli@novonordisk.com.ORCID https://orcid.org/0000-0002-6874-7405
Steven GoldbergJanssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com.
Ingo V HartungMedicinal Chemistry, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany ingo.hartung@merckgroup.com.ORCID https://orcid.org/0000-0001-8750-679X
Alexander HillischResearch and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany hartmut.beck@bayer.com jan.dreher@bayer.com alexander.hillisch@bayer.com.ORCID https://orcid.org/0000-0002-4228-2347
Evert HomanScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet Stockholm Sweden evert.homan@ki.se maurice.grube@scilifelab.se.ORCID https://orcid.org/0000-0002-9057-1848
Stefan KnappInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.ORCID https://orcid.org/0000-0001-5995-6494
Markus KösterBoehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com.
Oliver KrämerBoehringer Ingelheim International Binger Str. 173 D-55216 Ingelheim Germany menorca.chaturvedi@boehringer-ingelheim.com markus.koester@boehringer-ingelheim.com oliver.kraemer@boehringer-ingelheim.com.ORCID https://orcid.org/0000-0001-7607-1700
Josep LlaveriaA Division of Janssen-Cilag S.A., Janssen Research and Development Toledo Spain jbartolo@its.jnj.com JLlaveri@ITS.JNJ.com.ORCID https://orcid.org/0000-0003-2260-3657
Uta LesselBoehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Str. 65 D-88397 Biberach an der Riss Germany uta.lessel@boehringer-ingelheim.com.
Sven LindemannMerck KGaA Darmstadt Germany ulrich.betz@merckgroup.com Sven.Lindemann@merckgroup.com.ORCID https://orcid.org/0000-0002-0885-6175
Lars LinderothResearch & Early Development, Novo Nordisk A/S Måløv Denmark tgle@novonordisk.com lrli@novonordisk.com.
Hisanori MatsuiNeuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited Fujisawa Kanagawa Japan hisanori.matsui@takeda.com.ORCID https://orcid.org/0000-0002-4068-342X
Maurice MichelScience for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet Stockholm Sweden evert.homan@ki.se maurice.grube@scilifelab.se.
Florian MontelBoehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Str. 65 D-88397 Biberach an der Riss Germany florian.montel@boehringer-ingelheim.com.
Anke Mueller-FahrnowNuvisan Innovation Campus Berlin GmbH Müllerstraße 178 13353 Berlin Germany egner.target2035@web.de anke.mueller-fahrnow@nuvisan.com.ORCID https://orcid.org/0000-0002-2007-3659
Susanne MüllerInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.ORCID https://orcid.org/0000-0003-2402-4157
Dafydd R OwenDiscovery Network Group, Pfizer Medicine Design Cambridge MA 02139 USA Dafydd.Owen@pfizer.com.ORCID https://orcid.org/0000-0003-3106-7809
Kumar Singh SaikatenduGlobal Research Externalization, Takeda California, Inc. 9625 Towne Center Drive San Diego CA 92121 USA kumar.saikatendu@takeda.com.ORCID https://orcid.org/0000-0001-6734-237X
Vijayaratnam SanthakumarStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.ORCID https://orcid.org/0000-0002-7001-557X
Wendy SandersonJanssen Research & Development, Janssen Pharmaceutica N. V Beerse Belgium WSANDERS@its.jnj.com.
Cora ScholtenResearch and Development, Bayer AG, Pharmaceuticals 13353 Berlin Germany cora.scholten@bayer.com.
Matthieu SchapiraStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.ORCID https://orcid.org/0000-0002-1047-3309
Sujata SharmaJanssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com.
Brock ShiremanJanssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com.ORCID https://orcid.org/0000-0003-4062-0274
Michael SundströmStructural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet Stockholm Sweden kristina.edfeldt@ki.se michael.sundstrom@ki.se.
Matthew H ToddSchool of Pharmacy, University College London London WC1N 1AX UK mattoddchem@gmail.com.ORCID https://orcid.org/0000-0001-7096-4751
Claudia TredupInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt Frankfurt 60438 Germany knapp@pharmchem.uni-frankfurt.de tredup@pharmchem.uni-frankfurt.de.
Jennifer VenableJanssen Research and Development LLC San Diego California USA SGoldbe1@its.jnj.com ssharm505@ITS.JNJ.com BShirema@its.jnj.com JVenable@its.jnj.com.
Timothy M WillsonStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA tim.willson@unc.edu.ORCID https://orcid.org/0000-0003-4181-8223
Cheryl H ArrowsmithStructural Genomics Consortium, University of Toronto Toronto Ontario M5G 1L7 Canada suzanne.ackloo@utoronto.ca aled.edwards@utoronto.ca Cheryl.Arrowsmith@uhnresearch.ca.ORCID https://orcid.org/0000-0002-4971-3250
Funding
No grant is acknowledged in the PubMed record.
Abstract
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging 'open' principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.